Nxera Pharma’s Partner Neurocrine Biosciences Receives IND Acceptance from the FDA for Phase 2 Study of NBI-1117567 for Alzheimer's Cognition

Tokyo, Japan and Cambridge, UK, 26 August 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that its partner Neurocrine Biosciences Inc. (“Neurocrine”) has received IND Acceptance from the U.S. Food and Drug Administration (FDA) for a Phase 2 study of NBI-1117567 (“NBI-’567”) for Alzheimer's cognition. Nxera will receive an IND Acceptance milestone payment of US$10 million from Neurocrine pursuant to the agreement. The milestone payment is expected to be recognised in full as revenue in Q3 FY2026. NBI-’567 is an investigational, orally administered, muscarinic M1 receptor preferring agonist discovered using Nxera’s proprietary NxWave™ drug discovery platform.